Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Syntimmune is leveraging a deep understanding of FcRn biology to develop transformative therapies for patients with autoimmune diseases. The company has advanced rapidly into the clinic with its lead investigational candidate, a monoclonal antibody that rapidly inhibits pathogenic IgG and has potential as a pipeline-in-a-product in dermatology, rheumatology, hematology, neurology and nephrology.

List your booth number for exhibitions, ask us